Risankizumab (ABBV-066) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease and psoriatic arthritis.
Type of Molecule
Biologic
Target
IL-23
Region
n/a
| Potential Indication | Product Type | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Psoriasis | New Indication | Phase 3 |
| Psoriatic Arthritis | New Indication | Phase 2 |
| Crohn's disease | New Indication | Phase 2 |